Melanoma - a Model Disease for Scientific Innovation

About this episode

Dr. Ravi K. Amaravadi discusses the evolution of therapies for Stage IV metastatic melanoma and highlights innovations developed at Penn Medicine.

Clinician-researcher Ravi K. Amaravadi, MD, recalls a time within recent memory when no therapies existed for Stage IV metastatic melanoma, and reflects upon the 17 FDA-approved therapies now available to treat the disease. In this podcast, Dr. Amaravadi notes that many of these agents— including molecularly targeted therapy, immunotherapy in solid tumors, TIL cellular therapy, and personalized mRNA cancer vaccines—were pioneered at Penn Medicine. Learn more about Ravi K. Amaravadi, MD

People in this episode

Guest: Ravi K. Amaravadi, MD

Topics covered

• melanoma
• cancer treatment
• FDA-approved therapies
• scientific innovation
• immunotherapy
• personalized medicine

Keywords

• melanoma
• cancer therapies
• FDA approval
• immunotherapy
• mRNA vaccines
• targeted therapy
• TIL therapy

Mentioned in this episode

Organizations: Penn Medicine

Products: Stage IV metastatic melanoma, FDA-approved therapies, molecularly targeted therapy, immunotherapy in solid tumors, TIL cellular therapy, personalized mRNA cancer vaccines

More episodes of Penn Medicine Physician Interviews

• Advancing Meningioma Care: Precision Imaging and Targeted Therapies with DOTATATE PET, Lutathera, and GammaTile · June 8, 2026
• Advancing Meningioma Care: A Multidisciplinary Approach at Penn Medicine · May 15, 2026
• Proton Therapy As De-Intensification Strategy For HPV+ Head and Neck Cancers · April 1, 2026
• Muscle-Sparing Direct Anterior Approach To Total Hip Arthroplasty · March 13, 2026
• T Cell Lymphomas—Navigating The Journey From Diagnosis To Treatment And Beyond · March 13, 2026
• Gynecologic oncology: the known, the unknown, and the promising · February 26, 2026